Researchers have developed a synthetic molecule that selectively controls the physiological rewards of cocaine in mice. It also may represent a new class of small-molecule drugs that are more specific and have fewer side effects. The molecule selectively activates beta-arrestin without activating the G protein, making its signal to the cell much more specific.